Published in Am J Transplant on January 08, 2014
Study of Rituximab to Treat Chronic Renal Transplant Rejection (RituxiCAN-C4) | NCT00476164
Rituximab for Prevention of Rejection After Renal Transplantation | NCT00565331
RituxiMab INDuction in Renal Transplantation (ReMIND) | NCT01095172
Detection of C3d-binding donor-specific anti-HLA antibodies at diagnosis of humoral rejection predicts renal graft loss. J Am Soc Nephrol (2014) 1.60
Isolated endarteritis and kidney transplant survival: a multicenter collaborative study. J Am Soc Nephrol (2014) 0.94
Capillary C4d and Kidney Allograft Outcome in Relation to Morphologic Lesions Suggestive of Antibody-Mediated Rejection. Clin J Am Soc Nephrol (2015) 0.83
Immune-mediated vascular injury and dysfunction in transplant arteriosclerosis. Front Immunol (2015) 0.82
What's new in clinical solid organ transplantation by 2013. World J Transplant (2014) 0.81
The Effect of Bortezomib on Antibody-Mediated Rejection after Kidney Transplantation. Yonsei Med J (2015) 0.81
Characterization of transfusion-elicited acute antibody-mediated rejection in a rat model of kidney transplantation. Am J Transplant (2014) 0.80
MHC class I signaling: new functional perspectives for an old molecule. Tissue Antigens (2014) 0.80
Natural killer cells play a critical role in mediating inflammation and graft failure during antibody-mediated rejection of kidney allografts. Kidney Int (2016) 0.78
ABO-compatible liver allograft antibody-mediated rejection: an update. Curr Opin Organ Transplant (2015) 0.78
Memory CD4 T Cells Induce Antibody-Mediated Rejection of Renal Allografts. J Am Soc Nephrol (2016) 0.78
Clinically relevant interpretation of solid phase assays for HLA antibody. Curr Opin Organ Transplant (2016) 0.76
Updates on antibody-mediated rejection in intestinal transplantation. World J Transplant (2016) 0.76
Clinical significance of donor-specific human leukocyte antigen antibodies in liver transplantation. World J Gastroenterol (2015) 0.76
Eculizumab for the Treatment of Severe Antibody-Mediated Rejection: A Case Report and Review of the Literature. Case Rep Transplant (2016) 0.76
Antibody-Mediated Rejection: A Review. Ochsner J (2017) 0.75
Bortezomib-Containing Multimodality Treatment for Antibody-Mediated Rejection with Anti-HLA and Anti-AT1R Antibodies after Kidney Transplantation. Yonsei Med J (2017) 0.75
Donor-Specific HLA Antibody IgG Subclasses Are Associated with Phenotypes of Antibody-Mediated Rejection in Sensitized Renal Allograft Recipients. J Am Soc Nephrol (2015) 0.75
Heme Oxygenase-1 Inhibits HLA Class I Antibody-Dependent Endothelial Cell Activation. PLoS One (2015) 0.75
Mechanisms of antibody-mediated acute and chronic rejection of kidney allografts. Curr Opin Organ Transplant (2016) 0.75
The Impact of HLA Class I-Specific Killer Cell Immunoglobulin-Like Receptors on Antibody-Dependent Natural Killer Cell-Mediated Cytotoxicity and Organ Allograft Rejection. Front Immunol (2016) 0.75
Effectiveness of Intravenous Immunoglobulin Plus Plasmapheresis on Antibody-mediated Rejection or Thrombotic Microangiopathy in Iranian Kidney Transplant Recipient. Nephrourol Mon (2015) 0.75
mTOR inhibitor versus mycophenolic acid as the primary immunosuppression regime combined with calcineurin inhibitor for kidney transplant recipients: a meta-analysis. BMC Nephrol (2015) 0.75
From Humoral Theory to Performant Risk Stratification in Kidney Transplantation. J Immunol Res (2017) 0.75
Acute antibody-mediated rejection after intestinal transplantation. World J Transplant (2016) 0.75
Intravenous immunoglobulin therapy in kidney transplant recipients with de novo DSA: Results of an observational study. PLoS One (2017) 0.75
Rabbit anti-human thymocyte immunoglobulin for the rescue treatment of chronic antibody-mediated rejection after pediatric kidney transplantation. Pediatr Nephrol (2017) 0.75
Transplantation tolerance: don't forget about the B cells. Clin Exp Immunol (2017) 0.75
Blockade of HLA Antibody-Triggered Classical Complement Activation in Sera From Subjects Dosed With the Anti-C1s Monoclonal Antibody TNT009-Results from a Randomized First-in-Human Phase 1 Trial. Transplantation (2017) 0.75
Placental C4d deposition is a feature of defective placentation: observations in cases of preeclampsia and miscarriage. Virchows Arch (2015) 0.75
Desensitization in HLA-incompatible kidney recipients and survival. N Engl J Med (2011) 6.72
Improved graft survival after renal transplantation in the United States, 1988 to 1996. N Engl J Med (2000) 6.65
KDIGO clinical practice guideline for the care of kidney transplant recipients. Am J Transplant (2009) 6.43
Antibodies against MICA antigens and kidney-transplant rejection. N Engl J Med (2007) 5.31
Angiotensin II type 1-receptor activating antibodies in renal-allograft rejection. N Engl J Med (2005) 4.84
Rituximab and intravenous immune globulin for desensitization during renal transplantation. N Engl J Med (2008) 4.32
Alemtuzumab induction in renal transplantation. N Engl J Med (2011) 4.13
Immunosuppressive drugs for kidney transplantation. N Engl J Med (2004) 4.09
Long-term renal allograft survival in the United States: a critical reappraisal. Am J Transplant (2010) 4.09
Long-term renal allograft survival: have we made significant progress or is it time to rethink our analytic and therapeutic strategies? Am J Transplant (2004) 4.06
Understanding the causes of kidney transplant failure: the dominant role of antibody-mediated rejection and nonadherence. Am J Transplant (2011) 4.06
Rational development of LEA29Y (belatacept), a high-affinity variant of CTLA4-Ig with potent immunosuppressive properties. Am J Transplant (2005) 4.05
Lack of improvement in renal allograft survival despite a marked decrease in acute rejection rates over the most recent era. Am J Transplant (2004) 4.04
Antibody-mediated microcirculation injury is the major cause of late kidney transplant failure. Am J Transplant (2009) 3.43
Banff 2013 meeting report: inclusion of c4d-negative antibody-mediated rejection and antibody-associated arterial lesions. Am J Transplant (2014) 3.43
Capillary deposition of complement split product C4d in renal allografts is associated with basement membrane injury in peritubular and glomerular capillaries: a contribution of humoral immunity to chronic allograft rejection. J Am Soc Nephrol (2002) 3.34
Banff '09 meeting report: antibody mediated graft deterioration and implementation of Banff working groups. Am J Transplant (2010) 3.29
Campath-1H induction plus rapamycin monotherapy for renal transplantation: results of a pilot study. Am J Transplant (2003) 2.83
Identifying specific causes of kidney allograft loss. Am J Transplant (2008) 2.77
Preexisting donor-specific HLA antibodies predict outcome in kidney transplantation. J Am Soc Nephrol (2010) 2.66
Evidence for antibody-mediated injury as a major determinant of late kidney allograft failure. Transplantation (2010) 2.59
Consensus guidelines on the testing and clinical management issues associated with HLA and non-HLA antibodies in transplantation. Transplantation (2013) 2.55
Evolution and clinical pathologic correlations of de novo donor-specific HLA antibody post kidney transplant. Am J Transplant (2012) 2.46
A comparison of plasmapheresis versus high-dose IVIG desensitization in renal allograft recipients with high levels of donor specific alloantibody. Am J Transplant (2006) 2.37
Banff 2011 Meeting report: new concepts in antibody-mediated rejection. Am J Transplant (2012) 2.28
Endothelial gene expression in kidney transplants with alloantibody indicates antibody-mediated damage despite lack of C4d staining. Am J Transplant (2009) 2.27
De novo donor-specific antibody at the time of kidney transplant biopsy associates with microvascular pathology and late graft failure. Am J Transplant (2009) 2.24
Daclizumab versus antithymocyte globulin in high-immunological-risk renal transplant recipients. J Am Soc Nephrol (2009) 2.08
Pros and cons for C4d as a biomarker. Kidney Int (2012) 2.03
Non-HLA transplantation immunity revealed by lymphocytotoxic antibodies. Lancet (2005) 2.02
Terminal complement inhibition decreases antibody-mediated rejection in sensitized renal transplant recipients. Am J Transplant (2011) 1.98
A new diagnostic algorithm for antibody-mediated microcirculation inflammation in kidney transplants. Am J Transplant (2012) 1.93
Three-year outcomes from BENEFIT, a randomized, active-controlled, parallel-group study in adult kidney transplant recipients. Am J Transplant (2011) 1.93
Lack of effect in desensitization with intravenous immunoglobulin and rituximab in highly sensitized patients. Transplantation (2012) 1.93
Complement-fixing donor-specific antibodies identified by a novel C1q assay are associated with allograft loss. Pediatr Transplant (2011) 1.91
Three-year outcomes from BENEFIT-EXT: a phase III study of belatacept versus cyclosporine in recipients of extended criteria donor kidneys. Am J Transplant (2012) 1.90
Summary of FDA antibody-mediated rejection workshop. Am J Transplant (2011) 1.87
Kidney paired donation and optimizing the use of live donor organs. JAMA (2005) 1.82
Capillary deposition of C4d complement fragment and early renal graft loss. Kidney Int (1993) 1.80
Infusion of high-dose intravenous immunoglobulin fails to lower the strength of human leukocyte antigen antibodies in highly sensitized patients. Transplantation (2012) 1.78
Donor-specific HLA antibodies in a cohort comparing everolimus with cyclosporine after kidney transplantation. Am J Transplant (2012) 1.78
Complement activation in acute humoral renal allograft rejection: diagnostic significance of C4d deposits in peritubular capillaries. J Am Soc Nephrol (1999) 1.77
Chronic humoral rejection: identification of antibody-mediated chronic renal allograft rejection by C4d deposits in peritubular capillaries. J Am Soc Nephrol (2001) 1.72
One-year Results of the Effects of Rituximab on Acute Antibody-Mediated Rejection in Renal Transplantation: RITUX ERAH, a Multicenter Double-blind Randomized Placebo-controlled Trial. Transplantation (2016) 1.68
Evaluation of intravenous immunoglobulin as an agent to lower allosensitization and improve transplantation in highly sensitized adult patients with end-stage renal disease: report of the NIH IG02 trial. J Am Soc Nephrol (2004) 1.68
Outcome of subclinical antibody-mediated rejection in kidney transplant recipients with preformed donor-specific antibodies. Am J Transplant (2009) 1.67
Bortezomib provides effective therapy for antibody- and cell-mediated acute rejection. Transplantation (2008) 1.66
Significance of C4d Banff scores in early protocol biopsies of kidney transplant recipients with preformed donor-specific antibodies (DSA). Am J Transplant (2011) 1.66
NK cell transcripts and NK cells in kidney biopsies from patients with donor-specific antibodies: evidence for NK cell involvement in antibody-mediated rejection. Am J Transplant (2010) 1.62
Cryptic B cell response to renal transplantation. Am J Transplant (2013) 1.57
Baseline donor-specific antibody levels and outcomes in positive crossmatch kidney transplantation. Am J Transplant (2010) 1.56
Anti-HLA antibodies after solid organ transplantation. Transplantation (2000) 1.54
Comparison of combination Plasmapheresis/IVIg/anti-CD20 versus high-dose IVIg in the treatment of antibody-mediated rejection. Am J Transplant (2009) 1.52
Alemtuzumab induction therapy in kidney transplantation: a systematic review and meta-analysis. Transplantation (2012) 1.50
Banff 2003 meeting report: new diagnostic insights and standards. Am J Transplant (2004) 1.44
C1q-fixing human leukocyte antigen antibodies are specific for predicting transplant glomerulopathy and late graft failure after kidney transplantation. Transplantation (2011) 1.43
Transplant glomerulopathy: subclinical incidence and association with alloantibody. Am J Transplant (2007) 1.40
A new look at blockade of T-cell costimulation: a therapeutic strategy for long-term maintenance immunosuppression. Am J Transplant (2006) 1.40
Targeting B cells and antibody in transplantation. Am J Transplant (2011) 1.34
The use of antibody to complement protein C5 for salvage treatment of severe antibody-mediated rejection. Am J Transplant (2008) 1.34
Five-year outcomes in living donor kidney transplants with a positive crossmatch. Am J Transplant (2012) 1.31
Positive cross-match living donor kidney transplantation: longer-term outcomes. Am J Transplant (2009) 1.26
Molecular diagnosis of antibody-mediated rejection in human kidney transplants. Am J Transplant (2013) 1.25
C4d fixing, luminex binding antibodies - a new tool for prediction of graft failure after heart transplantation. Am J Transplant (2007) 1.24
The significance of the anti-class I antibody response. I. Clinical and pathologic features of anti-class I-mediated rejection. Transplantation (1990) 1.24
Analysis of MHC class II presentation of particulate antigens of B lymphocytes. J Immunol (1996) 1.24
Effect of antibodies on endothelium. Am J Transplant (2009) 1.23
Impact of rituximab therapy for treatment of acute humoral rejection. Clin Transplant (2009) 1.22
Donor-specific antibodies adversely affect kidney allograft outcomes. J Am Soc Nephrol (2012) 1.21
Chronic antibody-mediated rejection is reduced by targeting B-cell immunity during an introductory period. Am J Transplant (2011) 1.17
The significance of the anti-class I response. II. Clinical and pathologic features of renal transplants with anti-class I-like antibody. Transplantation (1992) 1.17
The acceptable mismatch program as a fast tool for highly sensitized patients awaiting a cadaveric kidney transplantation: short waiting time and excellent graft outcome. Transplantation (2004) 1.17
An integrated view of molecular changes, histopathology and outcomes in kidney transplants. Am J Transplant (2010) 1.16
Revisiting traditional risk factors for rejection and graft loss after kidney transplantation. Am J Transplant (2011) 1.14
Pretransplant donor-specific HLA class-I and -II antibodies are associated with an increased risk for kidney graft failure. Am J Transplant (2012) 1.13
Antibody-mediated rejection in kidney transplantation: a review. J Transplant (2012) 1.12
Presensitization: the problem and its management. Clin J Am Soc Nephrol (2006) 1.12
Endothelial transcripts uncover a previously unknown phenotype: C4d-negative antibody-mediated rejection. Curr Opin Organ Transplant (2010) 1.11
Serotyping for homotransplantation. XII. Occurrence of cytotoxic antibodies following kidney transplantation in man. Transplantation (1968) 1.11
The role of immunoglobulin-G subclasses and C1q in de novo HLA-DQ donor-specific antibody kidney transplantation outcomes. Transplantation (2013) 1.11
Reducing de novo donor-specific antibody levels during acute rejection diminishes renal allograft loss. Am J Transplant (2009) 1.11
Subclinical acute antibody-mediated rejection in positive crossmatch renal allografts. Am J Transplant (2007) 1.10
Impact of humoral alloreactivity early after transplantation on the long-term survival of renal allografts. Kidney Int (2001) 1.10
C4d-negative antibody-mediated rejection in renal allografts: evidence for its existence and effect on graft survival. Clin Nephrol (2011) 1.09
Efficacy, outcomes, and cost-effectiveness of desensitization using IVIG and rituximab. Transplantation (2013) 1.09
BAFF is increased in renal transplant patients following treatment with alemtuzumab. Am J Transplant (2009) 1.06
Medical care of kidney transplant recipients after the first posttransplant year. Clin J Am Soc Nephrol (2006) 1.05
Post-transplant anti-HLA class II antibodies as risk factor for late kidney allograft failure. Am J Transplant (2006) 1.03
B cell repopulation after alemtuzumab induction-transient increase in transitional B cells and long-term dominance of naïve B cells. Am J Transplant (2012) 1.03
The treatment of acute antibody-mediated rejection in kidney transplant recipients-a systematic review. Transplantation (2012) 1.03
MicroRNA sequence profiles of human kidney allografts with or without tubulointerstitial fibrosis. Transplantation (2012) 1.03
Chain transplantation: initial experience of a large multicenter program. Am J Transplant (2012) 1.02
Switching from calcineurin inhibitor-based regimens to a belatacept-based regimen in renal transplant recipients: a randomized phase II study. Clin J Am Soc Nephrol (2010) 1.01
Bortezomib: a new player in pre- and post-transplant desensitization? Nephrol Dial Transplant (2010) 1.00
Early and limited use of tacrolimus to avoid rejection in an alemtuzumab and sirolimus regimen for kidney transplantation: clinical results and immune monitoring. Am J Transplant (2009) 1.00
Implications of immunohistochemical detection of C4d along peritubular capillaries in late acute renal allograft rejection. Transplantation (2005) 0.98
Blockade of p-selectin is sufficient to reduce MHC I antibody-elicited monocyte recruitment in vitro and in vivo. Am J Transplant (2012) 0.98
Antibody-mediated rejection in kidney transplantation: an update. Expert Opin Pharmacother (2011) 0.96
Focal C4d+ in renal allografts is associated with the presence of donor-specific antibodies and decreased allograft survival. Am J Transplant (2009) 0.96
The sequence of the human genome. Science (2001) 101.55
The genome sequence of Drosophila melanogaster. Science (2000) 74.32
Lytic growth of Kaposi's sarcoma-associated herpesvirus (human herpesvirus 8) in culture. Nat Med (1996) 12.11
Role of domestic ducks in the propagation and biological evolution of highly pathogenic H5N1 influenza viruses in Asia. Proc Natl Acad Sci U S A (2005) 7.12
Kaposi's sarcoma-associated herpesvirus gene expression in endothelial (spindle) tumor cells. J Virol (1997) 6.61
H5N1 influenza: a protean pandemic threat. Proc Natl Acad Sci U S A (2004) 6.61
Emergence of multiple genotypes of H5N1 avian influenza viruses in Hong Kong SAR. Proc Natl Acad Sci U S A (2002) 6.17
Are ducks contributing to the endemicity of highly pathogenic H5N1 influenza virus in Asia? J Virol (2005) 5.78
The broad-spectrum antiviral ribonucleoside ribavirin is an RNA virus mutagen. Nat Med (2000) 5.73
H9N2 influenza viruses possessing H5N1-like internal genomes continue to circulate in poultry in southeastern China. J Virol (2000) 5.17
Understanding the causes of kidney transplant failure: the dominant role of antibody-mediated rejection and nonadherence. Am J Transplant (2011) 4.06
Activated antigen-specific CD8+ T cells persist in the lungs following recovery from respiratory virus infections. J Immunol (2001) 3.68
Identification of a novel coronavirus in bats. J Virol (2005) 3.48
Protection from respiratory virus infections can be mediated by antigen-specific CD4(+) T cells that persist in the lungs. J Exp Med (2001) 3.19
T cell infiltration of the prostate induced by androgen withdrawal in patients with prostate cancer. Proc Natl Acad Sci U S A (2001) 3.15
Avian influenza in Hong Kong 1997-2002. Avian Dis (2003) 2.90
Islet isolation assessment in man and large animals. Acta Diabetol Lat (1991) 2.89
The nucleotide sequence of chromosome I from Saccharomyces cerevisiae. Proc Natl Acad Sci U S A (1995) 2.74
The size and conformation of Kaposi's sarcoma-associated herpesvirus (human herpesvirus 8) DNA in infected cells and virions. J Virol (1996) 2.65
H5N1 influenza viruses isolated from geese in Southeastern China: evidence for genetic reassortment and interspecies transmission to ducks. Virology (2002) 2.55
Maturation cleavage required for infectivity of a nodavirus. J Virol (1992) 2.50
A novel mechanism to ensure terminal initiation by hepatitis C virus NS5B polymerase. Virology (2001) 2.21
A complex translational program generates multiple novel proteins from the latently expressed kaposin (K12) locus of Kaposi's sarcoma-associated herpesvirus. J Virol (1999) 2.16
A new diagnostic algorithm for antibody-mediated microcirculation inflammation in kidney transplants. Am J Transplant (2012) 1.93
Nicotinic receptor binding site probed with unnatural amino acid incorporation in intact cells. Science (1995) 1.92
Risk factors for chronic rejection in renal allograft recipients. Transplantation (1993) 1.90
Use of a repetitive element isolated from Mycobacterium tuberculosis in hybridization studies with Mycobacterium bovis: a new tool for epidemiological studies of bovine tuberculosis. Vet Microbiol (1993) 1.85
Antioxidant enzyme expression and reactive oxygen species damage in prostatic intraepithelial neoplasia and cancer. Cancer (2000) 1.85
De novo initiation of RNA synthesis by a recombinant flaviviridae RNA-dependent RNA polymerase. Virology (1999) 1.83
CUL-2 is required for the G1-to-S-phase transition and mitotic chromosome condensation in Caenorhabditis elegans. Nat Cell Biol (1999) 1.69
DLX-1, DLX-2, and DLX-5 expression define distinct stages of basal forebrain differentiation. J Comp Neurol (1999) 1.68
Cellular localization of latent murine cytomegalovirus. J Virol (1998) 1.62
Combined chemokine and cytokine gene transfer enhances antitumor immunity. Nat Med (1996) 1.61
The performance of three serum creatinine-based formulas in estimating GFR in former kidney donors. Am J Transplant (2006) 1.60
Description and clinical treatment of an early outbreak of severe acute respiratory syndrome (SARS) in Guangzhou, PR China. J Med Microbiol (2003) 1.58
Utility of flow cytometric detection of CD69 expression as a rapid method for determining poly- and oligoclonal lymphocyte activation. Clin Diagn Lab Immunol (1996) 1.51
Improvement in hypertension in patients with diabetes mellitus after kidney/pancreas transplantation. Circulation (2001) 1.50
Dose-response relations for unnatural amino acids at the agonist binding site of the nicotinic acetylcholine receptor: tests with novel side chains and with several agonists. Mol Pharmacol (1996) 1.50
Swinepox in pigs in northern Western Australia. Aust Vet J (1992) 1.47
Acceleration of type 1 diabetes by a coxsackievirus infection requires a preexisting critical mass of autoreactive T-cells in pancreatic islets. Diabetes (2000) 1.46
The impact of simultaneous pancreas-kidney transplantation on long-term patient survival. Transplantation (2001) 1.46
Acute potassium dichromate poisoning. Treated by peritoneal dialysis. Am J Dis Child (1970) 1.44
Pancreas after kidney transplants. Am J Surg (2001) 1.44
Prevalence and genetic diversity of human caliciviruses (HuCVs) in Mexican children. J Med Virol (2000) 1.43
Cellular immunity and memory to respiratory virus infections. Immunol Res (2001) 1.38
Naturally occurring Eperythrozoon ovis infection in sheep reduces wool production. Aust Vet J (1992) 1.38
Cryoglobulins. I. Studies on the nature, incidence, and clinical significance of serum cryoproteins in glomerulonephritis. J Lab Clin Med (1970) 1.35
Computerized analysis of mammographic parenchymal patterns for breast cancer risk assessment: feature selection. Med Phys (2000) 1.32
Immunosuppression with belatacept-based, corticosteroid-avoiding regimens in de novo kidney transplant recipients. Am J Transplant (2010) 1.31
Prednisone withdrawal in kidney transplant recipients on cyclosporine and mycophenolate mofetil--a prospective randomized study. Steroid Withdrawal Study Group. Transplantation (1999) 1.29
Emergency preparedness: a survey of dental practitioners. J Am Dent Assoc (1986) 1.26
Sequence data suggests big liver and spleen disease virus (BLSV) is genetically related to hepatitis E virus. Vet Microbiol (1999) 1.24
Hepatocyte nuclear factor 4alpha attenuates hepatic fibrosis in rats. Gut (2009) 1.24
Cryoglobulins. III. Further studies on the nature, incidence, clinical, diagnostic, prognostic, and immunopathologic significance of cryoproteins in renal disease. Q J Med (1975) 1.24
Manganese-containing superoxide dismutase overexpression causes phenotypic reversion in SV40-transformed human lung fibroblasts. Cancer Res (1996) 1.24
Monophyly of terrestrial adephagan beetles as indicated by three nuclear genes (Coleoptera: Carabidae and Trachypachidae). Zool Scr (2009) 1.23
Proteoglycans mediate cationic liposome-DNA complex-based gene delivery in vitro and in vivo. J Biol Chem (1998) 1.21
The EGFR mutation and its correlation with response of gefitinib in previously treated Chinese patients with advanced non-small-cell lung cancer. Ann Oncol (2005) 1.20
The pathogenesis of the renal lesion in a patient with streptococcal disease, infected ventriculoatrial shunt, cryogobulinemia and nephritis. Am J Med (1971) 1.20
Determinants of nicotinic receptor gating in natural and unnatural side chain structures at the M2 9' position. Neuron (1996) 1.19
Sapporo-like human caliciviruses are genetically and antigenically diverse. Arch Virol (1997) 1.16
Conversion of stable kidney transplant recipients from a twice daily Prograf-based regimen to a once daily modified release tacrolimus-based regimen. Transplant Proc (2005) 1.15
International epidemiological and microbiological study of outbreak of Salmonella agona infection from a ready to eat savoury snack--II: Israel. BMJ (1996) 1.15
Chylous ascites requiring surgical intervention after donor nephrectomy: case series and single center experience. Am J Transplant (2009) 1.15
Pathological and clinical characterization of the 'troubled transplant': data from the DeKAF study. Am J Transplant (2010) 1.14
Recombinant adeno-associated virus-mediated alpha-1 antitrypsin gene therapy prevents type I diabetes in NOD mice. Gene Ther (2004) 1.14
Cryoglobulins. II. The biological and chemical properties of cryoproteins in acute post-streptococcal glomerulonephritis. Int Arch Allergy Appl Immunol (1971) 1.14
Localization of antioxidant enzymes and oxidative damage products in normal and malignant prostate epithelium. Prostate (2000) 1.13
The tethered agonist approach to mapping ion channel proteins--toward a structural model for the agonist binding site of the nicotinic acetylcholine receptor. Chem Biol (2001) 1.13
Increased risk of fracture in patients receiving solid organ transplants. J Bone Miner Res (1999) 1.12
An update on avian influenza in Hong Kong 2002. Avian Dis (2003) 1.11
Test-retest reliability of the San Diego Odor Identification Test and comparison with the brief smell identification test. Chem Senses (2009) 1.11
Virus-specific cofactor requirement and chimeric hepatitis C virus/GB virus B nonstructural protein 3. J Virol (2000) 1.10
Sequencing of chromosome I from Saccharomyces cerevisiae: analysis of a 32 kb region between the LTE1 and SPO7 genes. Genome (1993) 1.10
CD30 defines a subset of activated human T cells that produce IFN-gamma and IL-5 and exhibit enhanced B cell helper activity. J Immunol (1994) 1.09
Total synthesis of fostriecin (CI-920). J Am Chem Soc (2001) 1.09
Somatostatin receptors 2 and 5 are preferentially expressed in proliferating endothelium. Br J Cancer (2005) 1.09
Overexpression of manganese superoxide dismutase in DU145 human prostate carcinoma cells has multiple effects on cell phenotype. Prostate (1998) 1.08
Specificity and kinetics of norovirus binding to magnetic bead-conjugated histo-blood group antigens. J Appl Microbiol (2010) 1.07
Template nucleotide moieties required for de novo initiation of RNA synthesis by a recombinant viral RNA-dependent RNA polymerase. J Virol (2000) 1.07
Computerized analysis of lesions in US images of the breast. Acad Radiol (1999) 1.06
BAFF is increased in renal transplant patients following treatment with alemtuzumab. Am J Transplant (2009) 1.06
Use of enzyme-linked immunoassays for antibody to types C and D botulinum toxins for investigations of botulism in cattle. Aust Vet J (1996) 1.06
Cationic liposome-mediated intravenous gene delivery. J Biol Chem (1995) 1.05
Long-term survival following kidney transplantation in 100 type I diabetic patients. Transplantation (1989) 1.04
Expression of mRNAs of multiple growth factors and receptors by astrocytes and glioma cells: detection with reverse transcription-polymerase chain reaction. Cell Mol Neurobiol (1995) 1.04
Microarray diagnosis of antibody-mediated rejection in kidney transplant biopsies: an international prospective study (INTERCOM). Am J Transplant (2013) 1.03
Steroid avoidance regimens: a comparison of outcomes with maintenance steroids versus continued steroid avoidance in recipients having an acute rejection episode. Am J Transplant (2007) 1.02
In vivo effects of recombinant IL-2. I. Isolation of circulating Leu-19+ lymphokine-activated killer effector cells from cancer patients receiving recombinant IL-2. J Immunol (1988) 1.01
Reassortants of H5N1 influenza viruses recently isolated from aquatic poultry in Hong Kong SAR. Avian Dis (2003) 1.01
Spectral characterization of catechol estrogen quinone (CEQ)-derived DNA adducts and their identification in human breast tissue extract. Chem Res Toxicol (2003) 1.01
Potential impact of microarray diagnosis of T cell-mediated rejection in kidney transplants: The INTERCOM study. Am J Transplant (2013) 1.00
Validation of methodologies for quantifying isolated human islets: an Islet Cell Resources study. Clin Transplant (2009) 1.00
Adeno-associated virus vector-mediated IL-10 gene delivery prevents type 1 diabetes in NOD mice. Proc Natl Acad Sci U S A (2001) 1.00
Magnetic nanoparticles with core/shell structures. J Nanosci Nanotechnol (2008) 1.00
Induction of human monocyte IL-1 mRNA and secretion during anti-CD3 mitogenesis requires two distinct T cell-derived signals. J Immunol (1991) 1.00
Localization of the thioredoxin system in normal rat kidney. Free Radic Biol Med (2001) 1.00
Diffuse familial nephropathy: a clinicopathological study. J Pediatr (1970) 0.99
Generation and characterization of a hepatitis C virus NS3 protease-dependent bovine viral diarrhea virus. J Virol (2000) 0.99
Glomerular lesions produced by autologous serum and autologous IgG modified by treatment with a culture of a -haemolytic streptooccus. J Med Microbiol (1972) 0.99